Evidence map›Paper›PMID 27940551›Full record

ReviewJournal of investigative medicine : the official publication of the American Federation for Clinical Research2017

Management of alcohol misuse in patients with liver diseases.

Jennifer L Peng, Milan Prakash Patel, Breann McGee, Tiebing Liang, Kristina Chandler, Sucharat Tayarachakul, Sean O'Connor, Suthat Liangpunsakul

Abstract readReview
In one paragraph

Review in Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Attacking Alcohol-Related Liver Disease by Taxing Alcohol Sales.Alcoholism, clinical and experimental research · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jennifer L PengDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University Medical Center, Indianapolis, Indiana, USA.
Milan Prakash PatelDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University Medical Center, Indianapolis, Indiana, USA.
Breann McGeeDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University Medical Center, Indianapolis, Indiana, USA.
Tiebing LiangDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University Medical Center, Indianapolis, Indiana, USA.
Kristina ChandlerDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University Medical Center, Indianapolis, Indiana, USA.
Sucharat TayarachakulDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University Medical Center, Indianapolis, Indiana, USA.
Sean O'ConnorDepartment of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Suthat LiangpunsakulDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University Medical Center, Indianapolis, Indiana, USA.
University Medical Center · USIndiana University – Purdue University Indianapolis · US

Funding

Translational Research and Evolving Alcoholic hepatitis Treatment (TREAT-IU)U01AA021840 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI NAGA P CHALASANI, Olawale Ojo · 2012 to 2026
$8.1M
Sestrin3 in the pathogenesis of alcoholic and non-alcoholic fatty liver diseaseR01DK107682 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI DONG, X. CHARLIE, LIANGPUNSAKUL, SUTHAT · 2016 to 2019
$1.4M
Long noncoding RNAs in alcoholic liver diseaseR21AA024935 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI LIANGPUNSAKUL, SUTHAT, WANG, LI · 2016 to 2017
$431k
Serum Proteomic Profiles as Biomarkers of Abusive Alcohol ConsumptionI01CX000361 · VA · RLR VA MEDICAL CENTER · PI LIANGPUNSAKUL, SUTHAT · 2012 to 2025
–
CSRD VA I01 CX000361NIAAA NIH HHS R21 AA024935NIAAA NIH HHS U01 AA021840NIDDK NIH HHS R01 DK107682
6 · The paper itself

Abstract

Excessive alcohol use not only causes alcoholic liver disease (ALD) but also increases the risk of liver-related mortality in patients who already have other chronic liver diseases. Screening for alcohol misuse or alcohol use disorder (AUD) among patients with underlying liver disease is essential. This clinical review covers what is known about ALD, the impact of alcohol in patients with underlying liver diseases, current management of alcohol misuse and AUD, and the management of alcohol misuse and AUD specifically in patients with liver diseases. Several treatment options for alcohol misuse and AUD exist such as psychosocial intervention and behavioral and pharmacological therapies. The strategies used in the treatment of alcohol misuse and AUD are still applicable in those who consume alcohol and have underlying liver disease. However, certain medications still need to be carefully used due to potentially worsening already compromised liver function. Screening of ongoing alcohol use in subjects with liver disease is important, and prompt intervention is needed to prevent the associated morbidity and mortality from the detrimental effects of continued alcohol use on underlying liver disease. Considering alcoholism is a complex disease, probably a multidisciplinary approach combining psychotherapy and comprehensive medical care will be the most effective. Future research could focus on identifying additional treatment options for addressing the psychotherapy component since the self-determination and will to quit drinking alcohol can play such a crucial role in promoting abstinence.

Indexed as

EthanolFatty LiverHumansLiver DiseasesLiver Diseases, AlcoholicMass ScreeningEthanolAlcohol DrinkingDisease ManagementLiver Diseases

Identifiers

PMID27940551
PMCPMC5495189
OpenAlexW2560338154

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.